Indeed, the role of altered GR expression, different isoforms due to alternative splicing, posttranslational modifications, availability of the ligand and nuclear receptor crosstalk have been suggested to modulate GR action in steroid-sensitive tissues and diseases (e.g., asthma, inflammatory bowel diseases), and in cancer as well. This evidence concerns the gene NR3C1 and cancer.